Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001104659-24-076885
Filing Date
2024-07-01
Accepted
2024-07-01 17:00:58
Documents
5
Effectiveness Date
2024-07-01

Document Format Files

Seq Description Document Type Size
1 FORM S-8 tm2418481d1_s8.htm S-8 75087
2 EXHIBIT 5.1 tm2418481d1_ex5-1.htm EX-5.1 10989
3 EXHIBIT 23.2 tm2418481d1_ex23-2.htm EX-23.2 2477
4 EX-FILING FEES tm2418481d1_ex-filingfees.htm EX-FILING FEES 10591
5 GRAPHIC tm2418481d1_ex5-1img001.jpg GRAPHIC 4241
  Complete submission text file 0001104659-24-076885.txt   106435
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-280644 | Film No.: 241091575
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)